<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33321">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672865</url>
  </required_header>
  <id_info>
    <org_study_id>5150301</org_study_id>
    <nct_id>NCT02672865</nct_id>
  </id_info>
  <brief_title>Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer</brief_title>
  <official_title>Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine safety and tolerability of adjuvant hyperthermic
      intraperitoneal chemotherapy (HIPEC) with mitomycin and cisplatin in subjects with locally
      advanced gastric cancer undergoing standard surgical resection. Subjects will be treated
      with HIPEC using a single dose each of mitomycin 15mg/m2 and cisplatin 50mg/m2 at 41-42 C
      for 90 minutes, during the definitive surgical procedure for gastric cancer. HIPEC will be
      performed after resection but before anastomosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment Plan:

      Patients undergoing definitive resection for gastric cancer and meeting the eligibility
      criteria will be treated with HIPEC using a single dose each of Mitomycin 15mg/m2 and
      Cisplatin 50mg/m2 at 41-42 C for 90 minutes. HIPEC will be performed after resection but
      before anastomosis. Both Cisplatin and Mitomycin are commercially available chemotherapeutic
      agents and will be obtained as marketed drugs.

      Outcome Measures:

      Patients will be followed up for 90 days following surgery and all postoperative
      complications will be recorded and graded according to the modified Clavien-Dindo
      classification.

      Schedule for Follow Up:

      Trial-related patient assessments will be performed daily while the patient remains in the
      hospital for postoperative care, and then at postoperative clinic visits. The final
      postoperative clinic visit for evaluation study outcomes and complications should occur
      between postoperative days 90 and 95 to allow for a cumulative assessment of the patient's
      perioperative complications, if any.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post Operative Complications</measure>
    <time_frame>90 days following surgery</time_frame>
    <description>Patients will be followed up for 90 days following surgery and all postoperative complications will be recorded and graded according to the modified Clavien-Dindo classification.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Locally Advanced Malignant Neoplasm</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The administration of hyperthermic intraperitoneal chemotherapy (HIPEC), using a warm solution of two chemotherapy medications (mitomycin and cisplatin) to bathe the internal surfaces of your abdomen in an attempt to kill any microscopic cancer cells that might be present on these surfaces.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperthermic Intraperitoneal Chemotherapy (HIPEC)</intervention_name>
    <description>Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of your abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.</description>
    <arm_group_label>HIPEC</arm_group_label>
    <other_name>HIPEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18-75 with biopsy-proven gastric adenocarcinoma

          2. Tumor clinically staged T3 or T4 and/or nodes staged clinically positive

          3. ECOG performance status &lt; 2

        Exclusion Criteria:

          1. Distant metastases

          2. Peritoneal carcinomatosis

          3. Synchronous malignancy

          4. Tumors at the gastroesophageal junction

          5. Recurrent gastric adenocarcinoma

          6. Creatinine &gt;/= 1.5

          7. Bilirubin &gt;/= 2

          8. INR &gt;/= 2

          9. Allergy to drugs included in the treatment plan

         10. Pregnancy

         11. Contraindication to major surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maheswari Senthil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maheswari Senthil, MD</last_name>
    <phone>909-558-4000</phone>
    <phone_ext>15948</phone_ext>
    <email>msenthil@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikki McCutchan, BS</last_name>
    <phone>909-651-5948</phone>
    <email>nmccutchan@llu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University Cancer Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maheswari Senthil, MD</last_name>
      <phone>909-558-4000</phone>
      <phone_ext>15460</phone_ext>
      <email>msenthil@llu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol. 2016 Jan 21;22(3):1114-30. doi: 10.3748/wjg.v22.i3.1114. Review.</citation>
    <PMID>26811651</PMID>
  </results_reference>
  <results_reference>
    <citation>Suo T, Mahteme H, Qin XY. Hyperthermic intraperitoneal chemotherapy for gastric and colorectal cancer in Mainland China. World J Gastroenterol. 2011 Feb 28;17(8):1071-5. doi: 10.3748/wjg.v17.i8.1071.</citation>
    <PMID>21448361</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 12, 2016</lastchanged_date>
  <firstreceived_date>February 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Maheswari Senthil</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
